BACKGROUND:: Cetuximab is a recombinant human/mouse chimeric epidermal growth
factor receptor (EGFR) monoclonal antibody. It was approved by the US Food and Drug …

Background Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth
factor receptor (EGFR), has activity against colorectal cancers that express EGFR. Methods …

Purpose To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients
with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth …

Abstract▴ Cetuximab is a chimeric monoclonal antibody highly selective for the epidermal
growth factor receptor (EGFR), which is over-expressed by 25–80% of colorectal cancer …

The recent successful development of monoclonal antibodies that target key components of
biological pathways has expanded the armamentarium of treatment options for patients with …

Purpose To establish evidence of activity, or lack thereof, of cetuximab-based therapy in
patients with refractory colorectal cancer with tumors that do not demonstrate epidermal …

In patients with metastatic colorectal cancer, the use of cetuximab currently requires a
documented tumoral epidermal growth factor receptor positivity. Responses to cetuximab …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …

Purpose This multicenter study evaluated the antitumor activity of cetuximab, an
immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in …

Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …